Glioma Supra Marginal Incision Trial
High Grade GliomaG-SUMIT is a pilot, phase II,randomized controlled trial to evaluate the feasibility of performing a large-scale trial in patients undergoing surgery for first-time diagnosis of high grade glioma (HGG) in a surgically favorable anatomical location to answer the following:
Does extending the margin of resection 1 cm beyond visible enhanced volume on MRI result in (a) an increase in overall survival? (b) result in a similar rate of "clinically-significant" neurological worsening during 30 days post surgery and quality of life at 6 and 12 months?
null
Participation Requirements
-
Sex:
ALL -
Eligible Ages:
18 to 85
Participation Criteria
Inclusion Criteria:
1. Radiographic evidence of a GAD-enhancing intra-axial tumor consistent with HGG;
2. Age ≥18 ≤ 85 years;
3. Karnofsky Performance Score ≥ 60;
4. Location of tumor in a safe anatomical location and
5. Patient or substitute decision maker (SDM) able to understand and consent to study participation.
Exclusion Criteria:
1. Multi-focal tumor, gliomatosis cerebri (≥3 lobes of the brain affected), tumors crossing the midline, or leptomeningeal enhancement;
2. Previous craniotomy for tumor excision (stereotactic biopsy is permitted);
3. Known metastatic cancer;
4. Uncorrectable coagulopathy;
5. Unable to obtain GAD-enhanced brain MRI.
Study Location
Sunnybrook Health Sciences Centre
Sunnybrook Health Sciences CentreToronto, Ontario
Canada
Contact Study Team
St Michael's Hospital
St Michael's HospitalToronto, Ontario
Canada
Contact Study Team
Mackenzie Health Sciences Center
Mackenzie Health Sciences CenterEdmonton, Alberta
Canada
Contact Study Team
University of Saskatchewan
University of SaskatchewanSaskatoon, Saskatchewan
Canada
Contact Study Team
Jessica Grosskleg
[email protected]Kingston Health Sciences Centre
Kingston Health Sciences CentreKingston, Ontario
Canada
Contact Study Team
- Study Sponsored By
- Sunnybrook Health Sciences Centre
- Participants Required
- More Information
- Study ID:
NCT04737577